Related Experiment Video
Updated: Jul 10, 2026
03:23
Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
Published on: May 10, 2024
Panallergen sensitization in children with eosinophilic esophagitis: a pilot study
Raffaella De Santis1, Valentina Silvera1, Cristina Ferrigno1
1Department of Paediatrics, Buzzi Children's Hospital, University of Milan, Milan, Italy.
Frontiers in Allergy
|July 9, 2026
Summary
Panallergen sensitization, including profilins and lipid transfer proteins (LTPs), is linked to poor treatment response in pediatric eosinophilic esophagitis (EoE). This suggests panallergen testing may guide therapy for EoE patients.
Area of Science:
- Immunology
- Allergy
- Gastroenterology
Background:
- Eosinophilic esophagitis (EoE) is a chronic immune disorder linked to atopy, potentially representing a late stage of the atopic march.
- Understanding comorbidities and allergen sensitization is crucial for managing pediatric EoE.
- Panallergen sensitization may influence treatment outcomes in EoE.
Purpose of the Study:
- To determine the prevalence of atopic comorbidities and sensitization to food allergens and panallergens in pediatric EoE patients.
- To investigate the association between panallergen sensitization and response to proton pump inhibitor (PPI) therapy in pediatric EoE.
Main Methods:
- A single-center observational study included pediatric EoE patients.
- Data collected included clinical, endoscopic, and histological findings, alongside sensitization profiles for food allergens and panallergens (profilins, PR-10 proteins, LTPs).
- Patients were grouped based on response to PPI therapy: histological remission (Group 1) versus non-response or relapse (Group 2).
Main Results:
- Of 24 pediatric patients, 71% had food allergen sensitization and 63% had panallergen sensitization.
- Group 2 (poor PPI responders) showed significantly higher rates of panallergen sensitization (78% vs. 17%) and atopic dermatitis (56% vs. 17%) compared to Group 1.
- Sensitization to profilins and lipid transfer proteins (LTPs) was associated with a lack of response to PPI therapy.
Conclusions:
- This study is the first to examine panallergen sensitization in pediatric EoE patients.
- Findings suggest a potential link between panallergen sensitization and reduced response to PPI therapy in pediatric EoE.
- Further large-scale studies are needed to confirm these preliminary results and their clinical implications.
Related Concept Videos
02:06Allergic Reactions
Overview
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:30Allergic Reactions: Anaphylaxis
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:29Asthma-I: Introduction
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...